HCW starts Assembly Biosciences at neutral; PT $3.50

Assembly Biosciences

H.C.Wainwright initiated coverage of Assembly Biosciences (NASDAQ:ASMB) with a “neutral” rating and price target of $3.50. The stock closed at $3.23 on Sept. 10.

Assembly is focused on developing treatments for chronic hepatitis B virus (HBV) infections and specifically, a finite cure for patients infected with HBV, writes analyst ED Arce. 

HBV is well-recognized as a significant global health issue, with an estimated prevalence of more than 270 million individuals globally. Despite this, the currently approved HBV treatments only have an estimated cure rate of under 5%, and require life-long treatments. 

“Assembly’s approach to providing a sustainable, finite cure for HBV patient include its development of HBV core inhibitors that are designed to terminate viral HBV DNA replication, while exploring the potential of utilizing core inhibitors in a combination with other HBV treatments with distinct mechanisms of action,” Mr. Acre said.

“The ultimate goal of such treatment combination is to provide a functional cure by suppressing HBV replication, then eventually eliminating HBV DNA all together,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.